Global Therapeutic Apheresis Market 2026 – 2035

The size of the therapeutic apheresis market in the world is estimated at USD 3.84 billion in 2025 and is expected to grow to USD 4.18 billion in 2026 and reach about USD 8.94 billion in 2035 with a CAGR of 7.9% between 2026 and 2035. The expanding clinical use of therapeutic apheresis regimens in neurological, hematological, cardiovascular, renal and autoimmune diseases as a result of the American Society for Apheresis evidence-based guidelines establishing therapeutic apheresis as the standard of care across an expanding portfolio of more than 80 clinical indications, the increasing global prevalence of autoimmune and antibody-meditated diseases creating structural patient population growth across a multitude of apheresis indications categories, the progressive increasing use of apheresis able clinical infrastructure in developing countries as healthcare systems invest in the extracorporeal therapy technology required to deliver this specialized therapeutic modality to their populations, the rising clinical adoption of extracorporeal photopheresis for graft-versus-host disease and cutaneous T-cell lymphoma driven by expanding regulatory approval and clinical guideline endorsement, the growing deployment of LDL apheresis for familial hypercholesterolemia management as cardiovascular risk reduction requirements for high-risk patients are recognized beyond statin therapy limitations, and the continuous advancement of selective apheresis technologies enabling more targeted and clinically superior plasma purification than conventional centrifugation-based exchange collectively drive robust and sustained market growth throughout the forecast period.

Market Highlight

• The therapeutic apheresis market was dominated by North America, which had a market share of 38% in 2025.

• Asia Pacific will continue to experience the highest rate of CAGR of 10.6% in the period between 2026 and 2035.

• By the type of products, the disposables and consumables segment took a market share of about 46% in 2025.

• By product, the segment of apheresis devices is experiencing the highest CAGR of 8.6% between 2026 and 2035.

• By type of procedure, the therapeutic plasma exchange segment would have the highest market share of 42% in 2025, and the extracorporeal photopheresis segment is projected to have the best CAGR at 11.4% within the next six years of operation between the years 2026 and 2035.

• By indication, the hematological disorders segment delivered the largest market share of 31% in 2025; the autoimmune disorders segment will be growing at the quickest CAGR of 11.8% in 2026-2035.

• By end-user segment, the segment that will have the largest market share of 64% in 2025 will be the hospitals and academic medical centers segment with the fastest CAGR of 10.2% between 2026 and 2035.

Significant Growth Factors

The Therapeutic Apheresis Market Trends present significant growth opportunities due to several factors:

• ASFA Guidelines Expansion and Evidence-Based Indication Growth Driving Broad Clinical Adoption:

The most significant single factor in therapeutic apheresis clinical adoption worldwide is the periodic publication of updated American Society for Apheresis Guidelines for the Use of Therapeutic Apheresis in Clinical Practice - the internationally referenced evidence-based guideline that proposes over 80 clinical conditions as having ASFA Category I or II evidence designation that prompts clinical practice adoption, health system coverage of reimbursement, and institutional investment infrastructure at hospitals seeking to offer their patient populations guideline-concordant care.

The categorical evidence framework, with Category I (apheresis as first-line therapy, by consensus) through Category II (apheresis as supportive therapy, evidence in controlled or uncontrolled trials) to the optimal role of apheresis yet to be determined through Category IV (no substantial evidence of benefit or potentially harmful), in the ASFA guidelines gives the hierarchy of clinical validation that can translate scientific evidence into clinical practice guidance with the necessary authority to stimulate both a personal practitioner adoption and institutional investment in the program.

The latest ASFA guideline updates, such as the 10th edition, released in early 2025 have increased the number of conditions assessed under the portfolio to 108, reclassified several conditions into higher evidence categories due to the accumulated clinical trial evidence, and introduced new emergent indications, such as immune checkpoint inhibitor-associated complications and post-viral dysautonomia syndromes, which are conditions previously not considered as suitable for apheresis intervention. The international distribution of ASFA guidelines, which have been translated and approved by the International Society of Apheresis, the European Academy of Apheresis, and national apheresis societies in Europe, Asia, and Latin America, provides a coordinated international clinical adoption driver that encourages the growth of therapeutic apheresis practice concurrently across numerous geographical markets as guidelines updates are distributed by the international apheresis clinical community.

The scientific output of the autoimmune disease research field, in the form of new autoantibody characterizations, new pathogenic mechanism discoveries, and new clinical evidence of apheresis efficacy, is a self-sustaining virtuous cycle of scientific discovery, evidence accumulation in guidelines, and clinical adoption, which is self-perpetuating in the long run of the therapeutic apheresis market.

• Graft-Versus-Host Disease and Cutaneous T-Cell Lymphoma Driving ECP Market Expansion:

The increasing clinical uses of extracorporeal photopheresis, the specialized apheresis therapy whereby the patient undergoes apheresis, the extracorporeal separation of lymphocytes, ex vivo exposure to the photosensitizing agent 8-methoxypsoralen, and UV irradiation that induces lymphocyte apoptosis and generates immunomodulatory effect through the activation of tolerogenic dendritic The graft-versus-host disease application - the most commonly used clinical indication of ECP in the world since its integration into the major GvHD management guidelines such as the National Comprehensive Cancer Network guidelines, as well as the European Society for Blood and Marrow Transplantation guidelines, as a second-line therapy to steroid-refractory acute and chronic GvHD - produces high volumes of procedures at hematology and transplant centers where the increasing number of allogeneic hematopoietic stem cell transplants generates correspondingly increasing GvHD management demand.

The clinical background that has put ECP on the list of standard second-line therapeutic recommendations in published guidelines on how GvHD should be managed is the clinical evidence that supports the use of ECP in chronic GvHD, with multiple prospective cohort and retrospective studies reported to document response rates of 50-80% in steroid-resistant chronic GvHD of the skin, mucous membranes, liver and lung, which form the clinical basis of ECP as an effective second-line treatment option. The cutaneous T-cell lymphoma indication - the first indication approved by the FDA ever in the treatment of a disease (Sézary syndrome) by ECP - is still yielding high ECP volumes at dermatology and oncology centers, and the unusual mechanism of immunomodulation exhibited by ECP is providing disease management in a malignancy that has a poor response to conventional chemotherapy and is one of the most convincing cases of ECP providing an unprecedented response in a disease form that is not compatible with traditional chemotherapy approaches.

The growing ECP indication repertoire, such as research on Type 1 diabetes prevention, ulcerative colitis, and cardiac transplant rejection, is becoming increasingly enlarged to cover more clinical areas than the well-known GvHD, CTCL, and solid organ transplant indications, with clinical trial results from these emerging indications potentially adding substantially to ECP's addressable patient population within the forecast period.

What are the Major Advances Changing the Therapeutic Apheresis Market Today?

• Next-Generation Apheresis Platforms Integrating Multiple Procedure Capabilities:

The creation of next-generation therapeutic apheresis systems that combine multiple procedure type capabilities (including therapeutic plasma exchange, cytapheresis, immunoadsorption, ECP, and LDL apheresis) into a single versatile instrument platform is turning the alternative associated with the previous generation of single-procedure-type dedicated instruments to enable healthcare institutions to implement comprehensive apheresis programs at a lower capital cost per procedure type and also to deliver clinical teams the flexibility to conduct the entire range of indicated therapeutic apheresis procedures on a unified platform. The flexible platform architecture, such as the Spectra Optia platform developed by Terumo BCT to serve TPE, cytapheresis, ECP and stem cell collection applications using procedure-specific disposable kits and software protocols and the COM. TEC by Fresenius Kabi, which serves TPE, cytapheresis, LDL apheresis and stem cell collection applications using a common platform benefits capital efficiency that would not otherwise give the apheresis program a business case at a hospital where only one type of procedure would have sufficient warranted dedicated instrument investment.

The clinical operation benefits of multiprocedure platforms such as uniform training of nursing personnel through a common platform on the use of a single instrument system that requires lower maintenance of competency than maintaining multiple separate procedure-specific instruments, standard quality assurance and maintenance practices that would be applicable to all types of procedures, and integrated management of electronic data to produce documentation and procedure data are accelerating the adoption of multiprocedure platforms across both small and large apheresis institutions as institutions acknowledge the overall cost of the program benefit compared to maintaining separate procedure-specific instruments. The HEMO2life platform of Macopharma with its combination of stem cell processing and therapeutic apheresis, has the capability to perform cell selection of the clinical cell therapy as well as therapeutic depletion of the cells and the new platforms introduced by Chinese.

• LDL Apheresis Expansion for Cardiovascular Risk Reduction Beyond Statin Therapy:

The recent clinical adoption of LDL apheresis, the procedure where low-density lipoprotein and lipoprotein(a) are selectively taken out of the plasma of the patient by adsorption columns or by lipoprotein(a) apheresis selectively by precipitation based filtration, is creating an ascending market segment of cardiovascular therapeutic apheresis on the basis of the increasing number of patients with familial hypercholesterolemia who are not adequately lowering LDL-C with maximal statin plus PCSK9 inhibitor treatment, Familial hypercholesterolemia the most prevalent inherited cardiovascular risk disorder (affecting about 1 in 250 in heterozygous form and about 1 in 300,000 in homozygous form with androgens of LDL-C levels dramatically higher than normal) provides a ready population of patients with whom LDL apheresis can be used, and whose reported lack of response to statin and other pharmacological interventions in controlling LDL-C levels sufficiently (and who regulate cardiovascular risk) justifies the The PCSK9 inhibitor age - with evolocumab and alirocumab producing 50-60% incremental LDL-C reduction on top of statin therapy - has led to a decrease in the use of LDL apheresis in patients in whom a satisfactory LDL-C level is achieved with the pharmacological combination whilst also defining the most well-characterized LDL apheresis indication population in which the pharmacological combination has failed to achieve satisfactory LDL-C bound maintenance, namely homozygous FH patients and patients with high Lp( The lipoprotein(a) apheresis reference, which is backed by increasing observational and registry data of cardiovascular event reduction in high Lp(a) - Patients undergoing routine LDL/Lp(a) apheresis are beginning to gain clinical traction as the global cardiovascular community becomes more and more aware of Lp(a) as an independent cardiovascular risk factor, and the future LDL apheresis market may be determined by the ability to approve individual Lp(a)-lowering pharmaceutical therapies that will define a pharmacotherapy-eligible patient.

• Immunoadsorption Technology Advancement and Indication Expansion:

The progressive clinical and commercial growth of immunoadsorption - the selective plasma purification method involving the use of protein A, anti-IgG, or specific antigen columns to adsorb immunoglobulins or selective autoantibodies in separated plasma and retain other plasma proteins in the patient - is producing an increasing premium segment of the apheresis procedure known as immunoadsorption, which yields a higher selectivity in the removal of immunoglobulins of target sizes compared to The immunoadsorption clinical indication portfolio - which is severe antibody-mediated renal transplant rejection that needs pre-transplant desensitization or post-transplant rejection rescue, refractory systemic lupus erythematosus with high-titer anti-dsDNA antibodies, severe idiopathic dilated cardiomyopathy with cardiac autoantibodies and refractor myasthenia gravis with high-titer anti-AChR antibodies - are the conditions in which the selectivity of immunoadsorption of The protein An immunoadsorption column—invented by Excorim and commercialized as the Immunosorba column used widely in European clinical practice - uses high-affinity protein A-IgG binding to achieve almost complete IgG removal of separated plasma, and the regenerable column structure allows a series of adsorption-regeneration cycles in a single procedure run, lowering the cost per procedure of using the column compared to the single-use column design.

Clinical trials of novel antigen-specific immunoadsorption columns targeting a particular autoantibody, including anti-dsDNA, anti-phospholipid, or anti-glycoprotein IIb/IIIa, rather than general anti-immunoglobulin depletion have been underway at various research studies, and the potential of highly specific removal of an autoantibody without the need to remove any immunoglobulins other than the target is the theoretical ideal of therapeutic antibody removal that current non-specific immunoadsorption methods are attempting for pathogenic antibody removal, providing clinical advantages over conventional TPE that published clinical evidence is progressively validating.

The protein A immunoadsorption column — developed by Excorim and commercialized as the Immunosorba column, used extensively in European clinical practice — achieves near-complete IgG removal from separated plasma through high-affinity protein A-IgG binding, with the column's regenerable design enabling multiple adsorption-regeneration cycles within a single procedure session that reduces per-procedure material cost compared to conventional single-use column designs. Novel antigen-specific immunoadsorption columns — targeting specific autoantibodies such as anti-dsDNA, anti-phospholipid, or anti-glycoprotein IIb/IIIa rather than broad immunoglobulin depletion — are in clinical development at multiple research centers, with the prospect of highly targeted antibody removal without any depletion of unrelated immunoglobulins representing the theoretical ideal of therapeutic antibody removal that current non-specific immunoadsorption approaches approach but do not achieve for complex multi-antibody autoimmune conditions.

Category Wise Insights

By Product Type

Why Do Disposables & Consumables Lead the Market?

The highest product type segment at about 46% of the total market share in 2025 is disposables and consumables, wherein the single-use procedure set in the mandatory requirements of the infection control of patient safety and comprising all of the blood-contacting circuit of the apheresis system, which includes the tube system, centrifuge bowl or membrane module, needle sets, and separation bag system, produces the recurring revenue with the procedure volume proportionality that significantly reflects the overall annual market value of the apheresis system of sale of capital equipment.

A typical utilization of 200 600 procedures per annum, per installed apheresis workstation of each, across its procedure type mix, generates USD 80,000 350,000 in annual disposable revenue based on procedure type mix and pricing in the geographic market with ECP kits, immunoadsorption columns, and LDL apheresis disposables costing significantly more per-procedure consumable than standard TPE procedure sets, resulting in the installed base revenue multiplier effect that causes the market growth of disposables to be proportional to the A significant part of the cost of therapeutic plasma exchange programs, the replacement fluid portion (including the albumin solutions, fresh frozen plasma, and saline used instead of separated plasma in more traditional TPE procedures) is an important part of the cost of the program, as the size of the TPE volume is growing as the main medically suitable replacement fluid in the situations when the plasma protein replacement is needed. With both replacement demand as existing installed base machines enter end-of-life requiring upgrading to current generation equipment and new installation demand as the healthcare systems of developing nations and previously non-apheresis hospitals install first-generation apheresis equipment as the first generation of these machines, the fastest growth is anticipated in the Apheresis devices with a CAGR of 8.6% between 2026 and 2035.

By Procedure Type

Why Does Therapeutic Plasma Exchange Lead the Market?

Therapeutic plasma exchange is the dominant type of procedure in the market with the largest segment of about 42% of market share in 2025, given that TPE is the most generally applicable and most commonly performed type of therapeutic apheresis procedure worldwide—with ASFA Category I or II level of evidence across the widest range of distinct clinical conditions of any apheresis type of procedure—and that TPE is the type of procedure around which most apheresis programs are centered before progressive expansion to other types of procedures.

The wide range of indications of TPE includes neurological, hemolytic, kidney, and autoimmune disorders. — develops a diversified clinical demand base that maintains TPE volume regardless of the clinical course of a particular given condition and ensures stable procedure volume that warrants investment in apheresis programs at facilities with general patient populations not high-need specialty condition centers. Extracorporeal photopheresis is growing at the quickest rate of 11.4% through 2035 with the increasing GvHD treatment suggestion in increasing allogeneic transplant centers, the rising indications in solid organ transplant and in autoimmune illnesses that are broadening the clinical indication of ECP, and the distinctive immunomodulatory effect that defines ECP as a treatment modality in which anti-inflammatory but not overall immunosuppressive properties grant the treatment clinical benefits compared to pharmaceutical immunosuppression in illness.

By Indication

Why Do Hematological Disorders Lead the Market?

Hematological disorders have the highest indication segment of about 31% of total market share in 2025, which reflects both the presence of the most urgent emergency apheresis indications, TTP which requires urgent life-saving plasma exchange; sickle cell disease, which requires erythrocytapheresis to treat acute chest syndrome, and hyperviscosity syndrome which requires plasma exchange to reduce urgent viscosity, and the largest chronic procedure volume indication in extracorporeal photopheresis to treat GvHD and CTCL of the hematological category. Imperative mortality of TTP without prompt apheresis, providing the medically irreducible emergency TPE sign, motivates the capital investment in apheresis facilities at all tertiary medical centers with a hematological emergency, producing the institutional commitment to apheresis capacity, implying the base volume of procedures independent of elective indication volume. ECP as a form of GvHD and CTCL management is the highest indication of procedure volume chronic hematological apheresis, as the ever-increasing number of allogeneic stem cell transplants carried out worldwide, with a 3070% GvHD incidence each way depending on conditioning and donor factors, generates proportionally rising demand on ECP procedures at transplant centers. The autoimmune disorders are showing the quickest indication rate of CAGR of 11.8% during 2026-2035 due to the rapid characterization of autoimmune pathways by antibodies in various disorders.

By End-User

Why Do Hospitals & Academic Medical Centers Lead the Market?

The largest end-user segment, at about 64% of the market share in 2025 is hospitals and academic medical centers based on the concentration of the most clinically complex therapeutic apheresis indications, which necessitates multi-specialty physician coordination, blood banking and laboratory support, critical care backup capability, and specialist apheresis nursing expertise, which are consolidated in tertiary and academic hospital facilities where the complexity of patients and institutional resources is matched with the demanding clinical requirements of a comprehensive apheresis program.

The formation of the evidence base to support the expansion of indications of apheresis is also achieved through academic medical centers, which are the sites of the clinical trials that develop the evidence base that leads to the further expansion of indications precipitating further institutional investment incentive. The most rapid end-user growth is seen in specialty treatment centers with a CAGR of 10.2% between 2026 and 2035 as the category of specialty treatment center continues to develop progressive specialty ambulatory apheresis centers to support the increasing chronic indication populations (GvHD maintenance ECP, CTCL treatment programs, FH LDL apheresis and chronic neurological condition TPE maintenance end-users) who are benefiting due to the flexibility provided by the specialty treatment centers including their scheduling.

Report Scope

Regional Analysis

How Big is the North America Market Size?

The North America therapeutic apheresis market size is estimated at USD 1.46 billion in 2025 and is projected to reach approximately USD 3.16 billion by 2035, with a CAGR of 8.0% from 2026 to 2035.

Why Did North America Dominate the Market in 2025?

In 2025, the United States controls nearly 38% of worldwide market share, and its dominance of global leadership in apheresis and related therapeutic fields is supported by the center of activity of the majority of apheresis equipment manufacturers; the greatest number of allogeneic stem cell transplant centers and GvHD ECP procedure-driven demand; the institutional spirituality of ASFA whose guideline records operate the most influential fashion of clinical adoption before international copying, and the highest concentration of apheresis medicine specialists who have undergone one of the recognized fellowship programs and who provide.

The overall therapeutic apheresis reimbursement environment of the United States, where therapeutic plasma exchange, ECP, and LDL apheresis, coupled with cytapheresis procedures, have been identified by CMS as specific CPT codes, finds its place within the Medicare Physician Fee Schedule and hospital outpatient prospective payment system, offers the financial framework to invest in apheresis programs at hospitals beyond the few that are adequately endowed with the resources to support the procedures, and to the extent that well-established reimbursement platforms support the economics The institutional framework of the American Society of Apheresis, including the maintenance of evidence-based guidelines, fellowship training accreditation, board certification pathway, and quality improvement programs that have characterized the U.S. therapeutic apheresis specialty, forms a professional clinical ecosystem that supports the U.S. therapeutic apheresis practice with a volume and level of evidence-based rigor that characterizes North American clinical apheresis.

Why is Europe a Strategically Important Market?

The European therapeutic apheresis market is estimated to be about USD 998 million in 2025 and is predicted to be about USD 2.19 billion in 2035, with a CAGR of 8.2. Europe is a market of extreme strategic value with its center of gravity based on the fact that Germany is the largest therapeutic apheresis market in Europe - the largest concentration of dedicated apheresis centers in the entire European continent, the largest deployment of LDL apheresis programs in the world, with the German statutory health insurance offering complete reimbursement of FH LDL apheresis, and that both Fresenius Kabi and B. Braun are the two leading manufacturers of apheresis equipment in the world, with their headquarters being located in Germany. The LDL apheresis network of more than 200 dedicated LDL apheresis centers to treat the German FH patient population under GKV reimbursement is the most developed national LDL apheresis program in the world and the model that has been followed by other cardiovascular therapeutic apheresis programs in other European countries in increasingly adopting.

The NHS therapeutic apheresis infrastructure of the United Kingdom, consisting of regional apheresis centers at large NHS teaching hospitals, specialist ECP units at hematology and dermatology centers, and the NHS Blood and Transplant therapeutic apheresis service that actively provides national coordination, is the second-largest national therapeutic apheresis market in Europe with comprehensive coverage of the entire range of apheresis procedure types. The educational activities of the European Apheresis Academy, the European chapter of the International Society of Apheresis, and the European Apheresis Congress, once in every two years, are the combined components of the professional infrastructure that has supported European apheresis medicine in being a fully developed clinical specialty with well-established evidence-based practice guidelines.

Why is Asia Pacific the Fastest-Growing Market?

The fastest-growing regional market will be Asia Pacific with an estimated CAGR of 10.6% between 2026 and 2035 due to the historically innovative role of Japan in the development of apheresis technology, with Japanese manufacturers Asahi Kasei Medical, Nikkiso and Kaneka developing innovative LDL apheresis, cascade filtration, and immunoadsorption technologies, which have been widely deployed in the sophisticated apheresis infrastructure in Japan before international commercialization, the rapidly developing tertiary hospital apheresis programs in China, as Japan has a very distinctive innovation ecosystem related to apheresis, having first introduced LDL apheresis clinical application in the 1980s; it has developed the most extensive rheumatoid arthritis rheumapheresis program in the whole world and has pioneered early uptake of column based selective adsorption technologies such as the Prosorba column in rheumatoid arthritis and the Cellsorba column in inflammatory bowel disease, making it the most technologically advanced and clinically innovative apheresis market in Asia Pacific that drives regional technology adoption trends.

Why is the Middle East & Africa Region an Emerging Market?

The LAMEA region also shows high and rising development of therapeutic apheresis market because of the advanced tertiary hospitals in the Gulf Cooperation Council such as the comprehensive apheresis program of King Faisal Specialist Hospital in Saudi Arabia, the transplant and apheresis services of the Cleveland Clinic Abu Dhabi in the UAE, and the rising number of selective immunoadsorption in the Hamad Medical Corporation in Qatar, which are of international standard in all of the spectrum of type of therapeutic apheresis procedures such as ECP, LDL apheresis The high rate of familial hypercholesterolemia in the Middle East (estimated to be high compared to the rest of the world among groups with historical founder effects in the Gulf Arab communities) provides a clinically delimited LDL apheresis indication population that is increasingly finding service with the growing cardiovascular specialty programs of the major Gulf hospitals. Another important LAMEA market participant that contributes to the evidence base of apheresis in the world is Israel: Israel has a world-class apheresis program, complete ECP, TPE, and LDL apheresis at Sheba Medical Center, Hadassah University Hospital, and the largest Israeli academic centers, with clinical research publications that further advance the worldwide apheresis evidence base. South Africa has academic hospitals such as Groote Schuur Hospital and Charlotte Maxeke Johannesburg Academic Hospital, which have therapeutic apheresis programs that serve the most clinically complex populations of patients in the sub-Saharan African region.

Top Players in the Market and Their Offerings

• Terumo BCT Inc.

• Fresenius Kabi AG

• Haemonetics Corporation

• B. Braun Melsungen AG

• Asahi Kasei Medical Co. Ltd.

• Miltenyi Biotec GmbH

• Nikkiso Co. Ltd.

• Kaneka Corporation

• Mallinckrodt Pharmaceuticals (Uvadex/ECP)

• Photomedex Inc.

• Macopharma SAS

• Others

Key Developments

The market has undergone significant developments as industry participants seek to advance next-generation apheresis platform capabilities, expand extracorporeal photopheresis indication approvals, and respond to the accelerating global clinical demand for comprehensive therapeutic apheresis services across established and emerging indication portfolios.

• In October 2024: Terumo BCT declared the commercial release of its Spectra Optia System Software Version 13.0 - which consists of a new built-in ECP module that makes the Spectra Optia system capable of extracorporeal photopheresis procedures along with its previously current TPE, cytapheresis, and stem cell collection functions, making the Spectra Optia a 5-procedure all-inclusive apheresis workstation (instead of the current 4-procedure versatile platform).

• In January 2025: Fresenius Kabi announced an agreement with the German Society of Nephrology and the European Renal Association to run the DESENSITIZE trial - a prospective multicenter randomized controlled trial comparing immunoadsorption-based desensitization to standard plasmapheresis-based desensitization in highly sensitized kidney transplant candidates - in 24 European transplant centers.

The Therapeutic Apheresis Market is segmented as follows:

By Product Type

• Apheresis Devices (Centrifugation-Based Systems, Membrane-Based Systems, Photopheresis Systems, Selective Adsorption Platforms)

• Disposables & Consumables (Apheresis Sets, Tubing Kits, Plasma Filters, Adsorption Columns, ECP Kits)

• Replacement Fluids (Albumin Solutions, Fresh Frozen Plasma, Saline)

• Other Product Types (Anticoagulants, 8-MOP Uvadex, Software Platforms, UV Irradiation Lamps)

By Procedure Type

• Therapeutic Plasma Exchange (Conventional TPE, Membrane TPE)

• Cytapheresis (Leukocytapheresis, Erythrocytapheresis, Thrombocytapheresis, Stem Cell Collection)

• LDL Apheresis (Dextran Sulfate Cellulose, HELP, Direct Adsorption)

• Immunoadsorption (Protein A, Anti-IgG, Antigen-Specific Columns)

• Extracorporeal Photopheresis (ECP)

• Rheopheresis

• Other Procedure Types (Cascade Filtration, Cryofiltration, Thermofiltration)

By Indication

• Neurological Disorders (GBS, NMOSD, Myasthenia Gravis, Anti-NMDAR Encephalitis, CIDP, MS)

• Hematological Disorders (TTP, HUS, Sickle Cell Disease, Hyperviscosity Syndrome, Polycythemia Vera, GvHD, CTCL)

• Renal Disorders (ANCA-Vasculitis, Anti-GBM Disease, FSGS, Transplant Rejection)

• Cardiovascular Disorders (Familial Hypercholesterolemia, High Lp(a), Dilated Cardiomyopathy)

• Autoimmune Disorders (SLE, RA, Pemphigus, Systemic Sclerosis, ANCA Vasculitis)

• Other Indications (Drug Intoxication, Hypertriglyceridemia-Induced Pancreatitis, Cytokine Storm)

By End-User

• Hospitals & Academic Medical Centers (Level I Trauma Centers, University Hospitals)

• Dialysis Centers (Nephrology Units with Apheresis Capability)

• Specialty Treatment Centers (Dedicated Apheresis Units, Neurology Centers, Transplant Centers)

• Other End-Users (Oncology Centers, Military Healthcare, Research Institutes)

Regional Coverage:

North America

• U.S.

• Canada

• Mexico

• Rest of North America 

Europe

• Germany

• France

• U.K.

• Russia

• Italy

• Spain

• Netherlands

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• New Zealand

• Australia

• South Korea

• Taiwan

• Rest of Asia Pacific 

The Middle East & Africa

• Saudi Arabia

• UAE

• Egypt

• Kuwait

• South Africa

• Rest of the Middle East & Africa

Latin America

• Brazil

• Argentina

• Rest of Latin America